Drug Database
TR

triamcinolone (Trivaris / Trivaris)

✓ Approved

Merck & Co. · NR3C1 · 小分子

什么是 triamcinolone?

triamcinolone 是一种小分子,由Merck & Co.研发。该药已获批,用于治疗相关适应症,给药途径:Others、Injectable (Others)、Intraocular Injection。

药物档案

商品名Trivaris, Trivaris
公司Merck & Co.
药物类别小分子
分子靶点NR3C1
给药途径Others, Injectable (Others), Intraocular Injection
状态Approved

作用机制

分子靶点

triamcinolone 作用于 1 个分子靶点:

NR3C1nuclear receptor subfamily 3 group C member 1 (GR, GCCR)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

triamcinolone 针对 5 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Eye disordersDiabetic retinal oedema✓ Approved
Eye disordersDiabetic retinopathy✓ Approved
Eye disordersRetinal vein occlusion✓ Approved
Eye disordersUveitis✓ Approved
Eye disordersCystoid macular oedema✓ Approved

相关研究文献

PubMedOral diseases2026-11-19

Variation in Basal Serum Cortisol Levels During Treatment of Oral Lichen Planus With 0.5% Triamcinolone Acetonide Mouthrinses: A Prospective Observational Study.

Blanco-Aguilera Elena E, Gándara-Vila Pilar P, Sanmartín-Barragáns Valeria V, Rodríguez-García Javier J et al.

To evaluate changes in basal serum cortisol levels in patients with atrophic-erosive oral lichen planus (OLP) and oral lichenoid lesion (OLL) treated with 0.5% triamcinolone acetonide mouthrinses and to assess the occurrence of clinical manifestations associated with adrenal dysfunction. A prospective observational study was conducted in 68 patients with clinically and histopathologically confirmed atrophic-erosive OLP or OLL. Participants received 0.5% triamcinolone acetonide mouthrinses following a tapering regimen over 3 months. Basal serum cortisol levels were measured at baseline, after 30 days, and after 90 days of treatment. Clinical and demographic variables and treatment-related adverse effects were analyzed. Mean basal serum cortisol levels decreased from 17.05 ± 4.38 μg/dL at baseline to 8.79 ± 7.34 μg/dL after 1 month of treatment. Following dose tapering, serum cortisol levels (SCL) partially recovered to 11.94 ± 6.44 μg/dL at 3 months. No clinical manifestations of adrenal insufficiency were observed. Baseline SCL were significantly associated with serum cortisol concentrations after 1 month (r = 0.34; p < 0.05). Older patients exhibited smaller hormonal fluctuations during treatment. Triamcinolone acetonide induced a transient reduction in SCL without clinically relevant adrenal dysfunction, suggesting a limited systemic impact when administered a tapering regimen.

PMID 43053526
阅读全文 →
PubMedJournal of cosmetic dermatology2026-11-18

Efficacy of Laser-Assisted Intralesional Triamcinolone for Pathological Scars: A Systematic Review and Meta-Analysis.

Almutawaa Bader N BN, Almahzoum Kholoud K, Albannai Noof N, Alsuwailem Faisal Fahad FF et al.

Pathological scars result from aberrant wound healing and remain challenging to treat. Intralesional triamcinolone acetonide is the current mainstay of therapy. Recently, adjuvant laser therapy has emerged as a promising strategy to enhance drug penetration and modulate scar vasculature and collagen remodeling. This meta-analysis assesses the clinical efficacy of laser-assisted intralesional triamcinolone in the treatment of pathological scars. In March 2026, we conducted a systematic search of PubMed, Scopus, Web of Science, Embase, and the Cochrane Library for randomized controlled trials (RCTs) and non-randomized studies directly assessing laser plus intralesional triamcinolone. For the meta-analysis, we used R 4.5.0 with R Studio 2024.12.1 + 563. Our review included five RCTs and three non-randomized comparative studies. Six studies encompassing 248 patients were included in the meta-analysis. Compared with intralesional triamcinolone alone, laser combination therapy showed no significant difference in VSS/mVSS reduction (SMD = 0.28, 95% CI: -0.53 to 1.10, p = 0.496), with substantial heterogeneity (I2 = 83.1%). However, when compared with laser monotherapy, the combination significantly improved VSS/mVSS (SMD = -1.16, 95% CI: -1.85 to -0.48, p = 0.0008; I2 = 16.9%). Patient satisfaction appeared higher with combination therapy, but certainty was low, and the comparison with laser monotherapy was based on a single study. For VSS subscales vs. laser alone, combination therapy significantly improved vascularity, pliability, and height, but not pigmentation. Recurrence rates did not differ significantly between groups. Laser plus intralesional triamcinolone may improve scar scores and patient satisfaction compared with laser monotherapy, but current evidence does not demonstrate superiority over intralesional triamcinolone alone. Recurrence benefit remains uncertain. However, our findings are limited by the small number of RCTs and substantial heterogeneity. Future adequately powered RCTs with longer follow-up periods are warranted.

PMID 43047260
阅读全文 →
PubMedAnnals of African medicine2026-11-18

Comparative Efficacy of Transforaminal Epidural Platelet-rich Plasma and Triamcinolone in Lumbar Radicular Pain: A Prospective Randomized Controlled Study.

Singh Manish Kumar MK, Kumar Amit A, Singh Sarita S, Singh Garima G et al.

Lumbar radicular pain is a common cause of chronic disability. Transforaminal epidural steroid injections can provide short-term relief, but their use is limited by local and systemic adverse effects. Platelet-rich plasma (PRP), an autologous orthobiologic rich in growth factors, has emerged as a potential alternative because of its regenerative and anti-inflammatory properties. To compare the efficacy, patient satisfaction, and safety of fluoroscopy-guided transforaminal epidural injections of autologous PrecurCell® PRP and triamcinolone in patients with chronic lumbar radicular pain. This prospective randomized controlled study included 60 patients with unilateral lumbar radicular pain of more than 3 months' duration and a baseline Visual Analog Scale (VAS) score of at least 5. Participants were randomized to receive either 4 mL of autologous PrecurCell® PRP or triamcinolone with normal saline through a fluoroscopy-guided transforaminal epidural injection. Pain intensity and patient satisfaction were assessed at baseline and at 1 week, 2 weeks, 1 month, 3 months, and 6 months after the procedure. Both groups showed significant reductions in VAS scores from baseline (P < 0.001). The steroid group achieved maximal pain relief at 1 month, followed by progressive worsening through 6 months. The PRP group showed a later but more sustained improvement, with maximal benefit at 3 months that was maintained through 6 months. Patient satisfaction was significantly higher and more durable in the PRP group (P < 0.001). No major adverse events occurred in either group. Fluoroscopy-guided transforaminal epidural injection of autologous PrecurCell® PRP appears to be a safe and effective alternative to triamcinolone for chronic lumbar radicular pain, with more sustained pain relief and patient satisfaction over 6 months.

PMID 43049191
阅读全文 →
PubMedJournal of cosmetic dermatology2026-11-18

Efficacy and Safety of L-Carnosine-Containing Hyaluronate Injection for Facial Skin Hydration and Brightness: A Randomized, Controlled, Evaluator-Blinded Trial.

Li Zhanhong Z, Sun Jingfang J, Jin Zhehu Z, Guo Wei W et al.

L-carnosine, a dipeptide with superior antioxidant and antiglycation properties, serves as the core active component in this study. We aimed to evaluate the efficacy and safety of a novel injectable composite solution, which features L-carnosine in combination with non-crosslinked sodium hyaluronate, glycine, alanine, proline, and vitamin B2, for improving facial skin dryness and dullness. In this prospective, multicenter, randomized, evaluator-blinded, superiority clinical trial, 466 subjects were randomized 1:1 to receive either the composite solution injections every 4 weeks for three sessions (treatment group) or no intervention (control group). The control group served as a baseline reference for natural temporal changes. Efficacy was assessed using the Global Aesthetic Improvement Scale (GAIS), the Skin Dryness and Dullness Improvement Scale (SDDIS), the Allergan Fine Lines Scale (AFLS), and the Allergan Skin Roughness Scale (ASRS). A predefined superiority margin of 15% was set for between-group differences. Blinded evaluators used standardized photographs to score the scales. Safety was evaluated based on adverse events. From baseline to Week 12, the treatment group exhibited significantly superior improvements in GAIS, SDDIS, AFLS, and ASRS scores relative to the control group. Efficacy assessed at Week 12 further highlighted this advantage (GAIS: 86.49% vs. 5.26%, SDDIS: 82.88% vs. 5.70%, AFLS: 36.07% vs. 4.57%, ASRS: 47.49% vs. 5.02%; all p < 0.05). These findings were consistent across both full analyses and per-protocol analyses. Participant satisfaction was significantly higher in the treatment group (p < 0.05). Treatment-related adverse events occurred in 94/228 (41.23%) of treated participants, predominantly mild injection-site reactions (e.g., erythema, swelling) that resolved within 2 weeks. This randomized trial demonstrated that the LIVIGI Sodium Hyaluronate Composite Solution for Injection provided favorable clinical efficacy and acceptable safety in improving facial skin dryness and dullness, suggesting its potential as a promising option for skin quality enhancement in aesthetic practice. Furthermore, these findings underscore the growing role of multi-component synergistic formulations in the evolving field of mesotherapy.

PMID 43047077
阅读全文 →
PubMedJournal of cosmetic dermatology2026-11-18

Evaluation of Intralesional Triamcinolone Acetonide and Platelet-Rich Plasma Therapy in Patients With Mild Patch-Type Alopecia Areata.

Ülker Ramazan R, Özdemir İlknur Yorğun İY, Özkol Hatice Uce HU

Alopecia areata is a long-term autoimmune disease that causes hair loss in approximately 2% of people but does not result in permanent scarring. Intralesional corticosteroid treatment provides effective results; however, long-term use may lead to skin atrophy and telangiectasia. Platelet-rich plasma (PRP), an autologous blood-derived preparation, represents a patient-specific alternative that avoids steroid-related side effects. To compare the efficacy and safety of intralesional PRP and intralesional triamcinolone acetonide (ILTA) in patients with mild patch-type (S1) alopecia areata. This prospective study included patients aged 18-65 years with mild patch-type alopecia areata who were admitted to our clinic between March 2024 and March 2025 and had not received any previous treatment. Patients were allocated into two groups; both groups received a total of three sessions of treatment every 4 weeks. The primary endpoint was the change in SALT score from baseline to the 6th month. Secondary endpoints included the change in SALT score at the 3rd month, clinical response categories, hair pull test conversion, relapse rate during 6-month follow-up, and the adverse-event profile. SALT scores were calculated at baseline, 3 months, and 6 months. Sixty patients (41 males, 19 females; mean age 27.97 ± 7.36 years) completed the study. SALT scores decreased significantly in both groups (p < 0.001). The score decreased from 6.03 to 0.93 in the PRP group and from 6.07 to 1.27 in the ILTA group, with no statistically significant difference between groups (mean difference 0.30; 95% CI -0.77 to 1.37; p = 0.576). The very good response rate (≥ 75% improvement) at six months was 76.67% in the PRP group and 66.67% in the ILTA group. Relapse occurred in 3 of 60 patients (5.0%) during the 6-month follow-up (1/30 (3.33%) in the PRP group and 2/30 (6.67%) in the ILTA group). Both groups experienced only mild adverse events; no serious side effects were observed. In mild untreated patch-type alopecia areata, PRP showed similar efficacy to intralesional triamcinolone acetonide and may be considered an alternative treatment option for mild patch-type alopecia areata.

PMID 43047042
阅读全文 →
PubMedJournal of cosmetic dermatology2026-11-18

Efficacy and Safety of Sodium Hyaluronate Injection for Moderate-To-Severe Neck Wrinkles: A Multicenter, Single-Blind, Randomized, Parallel-Controlled Trial.

Zheng Ji-Na JN, Yang Jianming J, Yang Kai K, Liu Zhiyu Z et al.

Hyaluronic acid (HA) occupies the micro-environment of the dermal matrix, filling depressions and imparting a smooth appearance to the skin. HA fillers are widely used for wrinkle correction. Still, the efficacy and safety of ANN0032, a new HA-based injection, have not yet been assessed in clinical trials for moderate to severe neck wrinkles. To evaluate the efficacy and safety of ANN0032, a novel HA-based injection, for the correction of moderate-to-severe horizontal neck wrinkles. In this multicenter, randomized, single-blind, parallel-controlled trial, 156 subjects were randomized (1:1) to receive either ANN0032 treatment (n = 78) or an established HA filler Hearty (n = 78). The primary efficacy endpoint was the proportion of subjects achieving a ≥ 1-point improvement on the Allergan Transverse Neck Lines Scale (ATNLS) at Week 4 posttreatment, as assessed by blinded evaluators. At Week 4, ANN0032 demonstrated non-inferior improvement compared with Hearty, with 83.3% versus 71.8% of subjects achieving the primary endpoint (rate difference, 11.54%; 95% CI: -3.29% to 26.37%). Both groups showed comparable safety profiles with no serious adverse events reported. ANN0032, a HA-based filler, demonstrated non-inferior efficacy and a favorable safety profile compared to an established HA filler, Hearty, in improving moderate-to-severe neck wrinkles.

PMID 43047123
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多triamcinolone